Godelieve A M Tytgat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9313125/publications.pdf Version: 2024-02-01

42	1,416	471509 17	³⁴⁵²²¹ 36
papers	citations	h-index	g-index
42	42	42	2352
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
2	Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. JCO Precision Oncology, 2022, 6, e2000447.	3.0	4
3	Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy. Cancers, 2022, 14, 943.	3.7	4
4	A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children. Clinical Oncology, 2022, , .	1.4	0
5	Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review. Frontiers in Oncology, 2022, 12, .	2.8	3
6	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
7	Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications. Stem Cells and Development, 2021, 30, 59-78.	2.1	25
8	Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR. Cancers, 2021, 13, 150.	3.7	13
9	The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery. Journal of Personalized Medicine, 2021, 11, 161.	2.5	6
10	Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments. Journal of Personalized Medicine, 2021, 11, 270.	2.5	31
11	Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease. Clinical Cancer Research, 2021, 27, 5576-5585.	7.0	13
12	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
13	CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. Cancers, 2021, 13, 4261.	3.7	15
14	Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes. EJNMMI Research, 2021, 11, 81.	2.5	1
15	Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis. Cancers, 2021, 13, 4941.	3.7	1
16	Combining Hypermethylated RASSF1A Detection Using ddPCR with miR-371a-3p Testing: An Improved Panel of Liquid Biopsy Biomarkers for Testicular Germ Cell Tumor Patients. Cancers, 2021, 13, 5228.	3.7	18
17	Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature. Journal of Clinical Medicine, 2021, 10, 5558.	2.4	6
18	Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors. JCO Precision Oncology, 2021, 5, 1738-1748.	3.0	13

GODELIEVE A M TYTGAT

#	Article	IF	CITATIONS
19	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
20	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers, 2020, 12, 1776.	3.7	29
21	The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells. Cancers, 2020, 12, 3231.	3.7	14
22	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183
23	Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma. JCO Precision Oncology, 2020, 4, 291-306.	3.0	14
24	Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake. EJNMMI Research, 2020, 10, 78.	2.5	5
25	Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel. JCO Precision Oncology, 2019, 3, 1-11.	3.0	17
26	Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients. European Journal of Cancer, 2019, 111, 21-29.	2.8	17
27	Peripheral Stem Cell Apheresis is Feasible Post 1311odine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution. Clinical Cancer Research, 2019, 25, 1012-1021.	7.0	7
28	3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. European Journal of Cancer, 2018, 90, 102-110.	2.8	15
29	Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. European Journal of Cancer, 2017, 72, 235-243.	2.8	57
30	Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. European Journal of Cancer, 2017, 76, 188-196.	2.8	28
31	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer, 2017, 123, 1095-1105.	4.1	75
32	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology, 2016, 34, 3195-3203.	1.6	105
33	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer, 2016, 54, 149-158.	2.8	10
34	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics, 2015, 47, 1411-1414.	21.4	313
35	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. Journal of Molecular Diagnostics, 2015, 17, 43-52.	2.8	19
36	Differentiated Thyroid Carcinoma After 1311-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases. Thyroid, 2012, 22, 643-646.	4.5	32

GODELIEVE A M TYTGAT

#	Article	IF	CITATIONS
37	Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. Clinical Cancer Research, 2012, 18, 808-814.	7.0	30
38	The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma. European Journal of Cancer, 2011, 47, 1193-1202.	2.8	41
39	Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma. Cellular and Molecular Life Sciences, 2010, 67, 807-816.	5.4	51
40	Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. Clinical Chemistry, 2009, 55, 1316-1326.	3.2	65
41	Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both. Experimental Hematology, 2002, 30, 555-563.	0.4	9
42	Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL. European Journal of Cancer, 1995, 31, 603-606.	2.8	8